Atzori et al. investigated the role of VEGFR-1 in resistance to vemurafenib (a BRAF inhibitor), finding that melanoma cells expressing VEGFR-1 were more invasive than VEGFR-1-deficient cells, suggesting VEGFR-1’s involvement in metastatic tumor growth [29]. The gene discussed is FLT1; the disease is metastatic neoplasm.